本研究旨在分析将一种压力限制代谢组分包含于多模式麻醉(MMA)中对接受卵巢癌手术的患者的有效性。在65名卵巢癌患者中进行了对MMA几个变体的有效性的随机研究，年龄为55.6±10.3岁。在手术之前，进行了双侧TAR阻滞。麻醉使用七氟烷来维持。镇痛使用利多卡因、硫酸镁、芬太尼和非甾体抗炎药。患者分为两组。在第1组(n=36)中，为了扩展MMA的压力限制能力，在手术前、手术中和接下来的三天中，使用了雷马沙。在第2组(n=29)中未使用雷马沙。研究了生化指标：POL/AOS、压力和抗压反应、C-反应蛋白、血红蛋白和肝酶的含量。手术前，接受检查的患者显示抗氧化系统调节失调、内源性中毒（EI）加重、全身炎症反应增强和酶代谢障碍。所获得的结果取决于所使用MMA的性质。在使用雷马沙作为MMA的代谢组分的组中，抗压反应动力学发生了变化，表现为一种有向的组间阻力增加的矢量，以及长期适应过程的优势发展，可以防止POL/AOS系统紊乱的形成，减少急性期蛋白、酶代谢障碍的浓度。在MMA中引入雷马沙可以改善抗痛保护的质量，促进POL产物的回归，防止肝病和EI的进展，有助于卵巢癌患者在手术前后围手术期内发展应激限制机制的长期适应。

The aim was to analyze the effectiveness of the inclusion of a stress-limiting metabolic component into multimodal anesthesia (MMA) in patients operated for ovarian cancer.A randomized study of the effectiveness of several variants of MMA was conducted in 65 patients with ovarian cancer 55.6±10.3 years old. Prior to the operation, a two-sided TAR block was performed. Anesthesia was maintained by sevoflurane. Analgesia was realized with lidocaine, magnesium sulfate, fentanyl, and nonsteroidal anti-inflammatory drugs. The patients were divided into 2 groups. In the 1st (n=36) group, in order to expand the stress-limiting capabilities of MMA, before surgery, intraoperatively and in the next three days, Remaxol was included. In the 2nd (n=29) group, Remaxol was not used. Biochemical parameters were studied: POL/AOS, stress and antistress reactions, the content of C-reactive protein, haptoglobin and liver enzymes.Before the operation, the examined patients revealed dysregulation of the antioxidant system, endogenous intoxication (EI), intensification of the systemic inflammatory response, and fermentopathy. The results obtained in the groups depended on the nature of the MMA used. In the group where Remaxol was used as a metabolic component of MMA, there was a change in the dynamics of antistress reactions, characterized by a directed intergroup vector of increased resistance, with a predominance of the development of long-term adaptation processes, allowing to prevent the formation of disorders in the POL/AOS system, to reduce the concentration of acute phase proteins, fermentopathy.The introduction of Remaxol into MMA improves the quality of antinociceptive protection, promotes regression of POL products, and prevents the progression of hepatopathy and EI, contributing to the development of stress-limiting mechanisms of long-term adaptation in patients with ovarian cancer in the intra and near perioperative period.